This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
Aged between 30 and 75 years, regardless of gender
Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years
Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined
Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%
The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome
Severe systemic diseases or functional impairments
Evidence of active infection or chronic infection, which may pose a risk to the subject
Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders
Shanghai UniXell Biotechnology Co., Ltd
Lead sponsor
Ruijin Hospital
Collaborator